Advanced Colorectal Polyps on Colonoscopy: A Trigger for Earlier Screening of Family Members

C. L. Molmenti
Zucker School of Medicine at Hofstra/Northwell

J. M. Kolb
J. J. Karlitz

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/publications

Part of the Epidemiology Commons

Recommended Citation

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.
Advanced Colorectal Polyps on Colonoscopy: A Trigger for Earlier Screening of Family Members

Christine L. Molmenti, PhD, MPH\(^1\), Jennifer M. Kolb, MD\(^2\) and Jordan J. Karlitz, MD\(^3\)


**INTRODUCTION**

Early screening of first-degree relatives (FDRs) of patients with colorectal cancer (CRC) has always been a clinical focus. However, the significant risk to FDRs of those with advanced colorectal polyps (ACPs) and the need for earlier initiation of screening may be overlooked. For the purposes of this manuscript, we use the term ACP to describe advanced adenomas (AAs) (the term traditionally used in the literature) and advanced serrated polyps.

Both CRC and ACPs diagnosed in a proband require FDRs (parents, siblings, and children) to be screened at 40 years of age or 10 years before the proband’s diagnosis, whichever is earlier (1). In addition, ACPs are high-risk lesions that warrant shorter surveillance intervals in the proband. Given the increasing incidence of early-onset CRC, it is imperative to increase awareness of ACPs among gastroenterologists, primary care physicians, and other providers to assure adherence to earlier screening among FDRs.

---

**Advanced Colorectal Polyp | GI brief**

An advanced colorectal polyp diagnosis has implications for both patients and their close relatives.

The National Colorectal Cancer Roundtable created the advanced colorectal polyp GI brief to help endoscopists and primary care clinicians identify patients with advanced colorectal polyps, understand the epidemiology and associated risk factors, and most importantly, know the risks of colorectal neoplasia for patients with advanced colorectal polyps and their first-degree relatives (parents, siblings, children).

**Objectives:**

1. Remind endoscopists that patients with an advanced colorectal polyp and their close relatives are at increased risk for advanced colorectal polyps and colorectal cancer.

2. Keep endoscopists up to date with current guidelines. Patients diagnosed with advanced polyp(s) require more frequent surveillance, and their close relatives require earlier and more frequent screening.

3. Provide template letters to communicate colonoscopy and pathology results, risk status, and follow-up recommendations for patients and close relatives.

---

*Figure 1.* National Colorectal Cancer Roundtable Advanced Colorectal Polyp GI brief. Reprinted with permission from the National Colorectal Cancer Roundtable, American Cancer Society. GI, gastrointestinal.
Herein, we provide a guide to (i) appreciate recommended surveillance intervals for patients with ACP and early screening for FDRs and (ii) communicate risk to patients with ACP and their FDRs. The impetus for this guide was the development of the Advanced Colorectal Polyp GI brief (2) (Figure 1) developed by the American Cancer Society and the National Colorectal Cancer Roundtable (NCCRT) Advanced Adenoma Working Group (https://nccrt.org/resource/advanced-colorectal-polyp-brief/).

DEFINITION AND EPIDEMIOLOGY OF ACPs

ACPs are defined as any one of the following: (i) tubular adenoma ≥ 1 cm or any adenoma with villous features or high-grade dysplasia regardless of the size, (ii) sessile serrated polyp (SSP) ≥ 1 cm or SSP with cytologic dysplasia, or (iii) traditional serrated adenoma of any size. ACPs are the immediate precursors of CRC (3) and critical target lesions for screening.

During screening colonoscopy, approximately 10% of average-risk individuals are diagnosed with an AA (4). AA prevalence is higher among men (5) but appears similar among blacks and whites (6). The prevalence of any SSP ranges from 2 to 9% among average-risk adults undergoing screening, with approximately half ≥ 1 cm (7) and <1% showing cytologic dysplasia (8). Traditional serrated adenomas are more rare (prevalence 0.1–2.3%) (9).

PRACTICE ADVICE FOR THE ENDOSCOPIST

Step 1. Define the patient at risk

Knowing a patient’s risk is essential to providing recommendations that can be lifesaving. Individuals with AAs have a 15.9%–19.3% risk of metachronous AA and 0.8%–1.3% risk of metachronous CRC (10). The recommended surveillance interval for ACPs is 3 years, with earlier follow-up for piecemeal or incompletely resected lesions (11).

FDRs of patients with AA carry a 1.68–3.90-fold increased risk of developing CRC and 6.05-fold increased odds of developing AAs compared with those without a family history (12,13). FDRs of patients with advanced serrated lesions may be at a similarly increased risk, but additional data are needed (1). The United Society Multi-Society Task Force recommends that FDRs of patients with AAs or advanced serrated lesions initiate screening at age 40 years or 10 years prior to the patient’s diagnosis, whichever is earlier (1) (Table 1). Early screening among FDRs of patients with ACP is underutilized and represents an area where gastroenterologists could have a larger impact on CRC prevention.

Table 1. Screening guidelines for first-degree relatives of patients with advanced adenoma

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Early screening guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>USMSTF AA or CRC in 1 FDR &lt; 60 yr of age or 2 FDRs (any age)</td>
<td>Colonoscopy every 5 yr beginning 10 yr before the age at diagnosis or at the age of 40 yr, whichever is earlier.</td>
</tr>
<tr>
<td>AA or CRC in 1 FDR ≥ 60 yr of age</td>
<td>Begin screening at 40 yr of age. Options for screening and intervals are the same as those for average-risk persons.</td>
</tr>
</tbody>
</table>

According to the USMSTF, when FDRs have documented advanced serrated lesions (SSPs ≥ 1 cm, SSP with cytologic dysplasia, or a TSA ≥ 1 cm*), there is no clear evidence as to how to proceed (unless the relative meets criteria for serrated polyposis syndrome). They recommend screening FDRs of persons with advanced serrated lesions similar to screening of FDRs of persons with advanced conventional adenomas (see ref. 1).

*Please note a TSA of any size is considered advanced for the proband surveillance (see ref. 11).

AA, advanced adenoma; CRC, colorectal cancer; FDR, first-degree relative; SSP, sessile serrated polyp; TSA, traditional serrated adenoma; USMSTF, United Society Multi-Society Task Force.

Figure 2. Risk communication flow. *Persons with a single first-degree relative diagnosed at ≥ 60 years with an advanced colorectal polyp can be offered average-risk screening options at age 40 years.
Sample Letter
Informing a Patient About Advanced Colorectal Polyps

[Letterhead]

[Date]

[Patient Address]

Dear [Patient]:

I would like to inform you of the results from your recent colonoscopy at [medical center] on [date]. As you know, a small growth called a polyp was removed from your colon (rectum) during the procedure. As expected, the polyp was benign (not cancer). Specifically, the polyp was a precancerous advanced adenoma (AND/OR advanced serrated polyp). If not removed, this type of polyp could have grown larger over many years and might have turned into colorectal cancer. Because you have a higher chance of developing new polyps and colorectal cancer, you should undergo a repeat colonoscopy in 3 years.

I would also recommend colorectal cancer screening for your first-degree relatives (brothers, sisters, children, and parents) beginning at age 40 [or 10 years before the youngest affected relative, whichever is earlier] - please be specific based on patient's age at the time polyps were removed. Make your family members aware of these results so that they can discuss beginning colorectal cancer screening earlier with their physician.

I would suggest you consider changing any health habits that might increase your chance of forming more precancerous polyps and thus colorectal cancer. You may lower your chance of developing future polyps and colorectal cancer by adopting healthy habits such as not smoking, maintaining a healthy body weight, being physically active, limiting red and processed meat (such as beef, cold cuts, bacon, and hot dogs), minimizing alcohol intake (or avoiding alcohol altogether), and eating a diet with a lot of fruits and vegetables.

Please feel free to contact me at [phone number] with any questions.

Stay well.

Sincerely

[Endoscopist name]
cc: [PCP]

Figure 3. Template letter included in the National Colorectal Cancer Roundtable Advanced Colorectal Polyp GI brief. GI, gastrointestinal. Reprinted with permission from the National Colorectal Cancer Roundtable, American Cancer Society.

Common clinical scenarios. Scenario #1. An asymptomatic 39-year-old man is referred to gastroenterology because his father had a 1.2-cm tubular adenoma at the age of 67 years. Recommendation: Because of a FDR with an AA, screening should commence at 40 years of age.

Scenario #2. A 64-year-old woman has a 1.1-cm tubular adenoma on screening colonoscopy. Recommendation: Surveillance colonoscopy in 3 years, and counsel patient that FDRs are at increased risk and should undergo screening at 40 years of age. In this scenario, the endoscopist needs to not only think about surveillance colonoscopy intervals in the proband but also be mindful of the increased risk to FDRs. Because gastroenterologists routinely make decisions about surveillance intervals (because of high polyp prevalence), surveillance guidelines are at the forefront of the physician’s approach, but communicating familial risk may potentially be overlooked. The patient should notify their children and siblings to talk to their physician about earlier screening.

Step 2. Take a thorough family history to exclude hereditary syndromes

Documenting the family history of CRC, colorectal polyps, and other malignancies in all patients is essential to identifying those with underlying hereditary cancer syndromes, including Lynch syndrome and others.

Furthermore, in the setting of multiple adenomas (lifetime cumulative adenomas and on a single colonoscopy), polyposis syndromes need to be considered. Patients with hereditary syndromes fall outside the average-risk screening guidelines. This also has implications for family members. The following strategies for collecting family history can be used, even in busy endoscopy units: (i) in advance of the visit, provide patients with family history worksheets, (ii) use a clinical prediction algorithm (i.e., PREMM 5 Model) to quantify the likelihood of a Lynch syndrome gene mutation (https://premm.dfci.harvard.edu), and (iii) refer to the NCCRT Risk Assessment and Screening Toolkit to Detect...
Step 3. Communicate risk to your patient and their FDRs

Postpolypectomy risk communication is critical for CRC prevention. Preliminary data show 80% of patients with adenoma are unaware that they may be at higher risk than the general population. 21% do not know follow-up is needed, and 68% have inaccurate knowledge of their results (Molmenti, unpublished data). Furthermore, multiple communication channels exist by which patients receive colonoscopy results and risk information with no standard of care established. A more streamlined approach to risk communication that begins with the patient and reaches FDRs may improve the quality of care we provide (Figure 2). It is recommended that all such communications be documented clearly in the medical record.

The use of a computer-based bedside educational tool, administered before discharge from endoscopy units in combination with personalized letters sent through mail, is effective at improving the patient’s knowledge of results and risk perception (for themselves and their relatives) and increases the likelihood that patients contact their relatives, compared with standard of care (14). Template letters developed by the NCCRT (2) can be downloaded online, tailored to your patient, and embedded as macros into electronic health record systems (https://nccrt.org/wp-content/uploads/GI-Brief_ADVANCED-POLYPS-Colonoscopy-Report-Letter_final.pdf) (Figure 3).

Another approach can be used at the time of endoscopy. If an adenomatous or sessile serrated appearing polyp $\geq 1\text{ cm}$ is found, a preliminary discussion regarding potential earlier screening of FDRs before discharge can be carried out (and documented in the colonoscopy report and discharge materials as there are often recall issues because of sedation or issues related to patient loss to follow up). A caveat is that occasionally, histology will reveal a nonprecancerous polyp (i.e., in situ or florid). A preliminary discussion regarding potential earlier screening of FDRs may improve the quality of care we provide (Figure 2). It is recommended that all such communications be documented clearly in the medical record.

FUTURE DIRECTIONS/SUMMARY

There has always been a focus on the risk to relatives after a proband’s CRC diagnosis, yet the United Society Multi-Society Task Force early screening guidelines for FDRs of patients with ACPs may be underappreciated. Improved strategies to communicate risk for colorectal neoplasia among probands and FDRs are imperative. Furthermore, there is a need to create a culture of awareness of ACPs among gastroenterologists, primary care physicians, and others, whereby patients are routinely asked not only about their family history of CRC but also about their family history of ACPs. By increasing the dialogue regarding these advanced lesions, we can continue to make meaningful progress toward reducing the overall burden of CRC, including early-onset disease.

ACKNOWLEDGMENTS

We would like to extend our sincere gratitude to Drs. Dennis Ahnen and Paul Schroy for their invaluable contributions to the development of this manuscript.

CONFLICTS OF INTEREST

Guarantor of the article: Christine L. Molmenti, PhD, MPH, and Jordan J. Karlitz, MD.

Specific author contributions: C.L.M. and J.J.K. were responsible for the idea. All authors were involved in drafting and critically revising the manuscript. All authors approved the final draft submitted.

Financial support: J.M.K. is supported in part by the NIH Gastrointestinal Diseases Training Grant (T32-DK007038).

Potential competing interests: J.J.K. at the time of publication: Advisor Exact Sciences, Consultant and Speakers Bureau Myriad Genetics, and equity position in Gastro Girl. C.M. at the time of publication: Consultant Pfizer. The contents in this manuscript do not necessarily reflect the views of the Department of Veterans Affairs or the U.S. Government.

REFERENCES